Infliximab in ulcerative colitis
Avi Levin, Oren ShiboletGastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, IsraelAbstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). I...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d7d25d975b084e1b95110d58fe7dcd89 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d7d25d975b084e1b95110d58fe7dcd89 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d7d25d975b084e1b95110d58fe7dcd892021-12-02T00:59:41ZInfliximab in ulcerative colitis1177-54751177-5491https://doaj.org/article/d7d25d975b084e1b95110d58fe7dcd892008-09-01T00:00:00Zhttp://www.dovepress.com/infliximab-in-ulcerative-colitis-a2288https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Avi Levin, Oren ShiboletGastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, IsraelAbstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the treatment of moderate to severe UC.Keywords: infliximab, ulcerative colitis, anti-TNF-α antibody, crohn’s disease Avi LevinOren ShiboletDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 379-388 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Avi Levin Oren Shibolet Infliximab in ulcerative colitis |
| description |
Avi Levin, Oren ShiboletGastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, IsraelAbstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the treatment of moderate to severe UC.Keywords: infliximab, ulcerative colitis, anti-TNF-α antibody, crohn’s disease |
| format |
article |
| author |
Avi Levin Oren Shibolet |
| author_facet |
Avi Levin Oren Shibolet |
| author_sort |
Avi Levin |
| title |
Infliximab in ulcerative colitis |
| title_short |
Infliximab in ulcerative colitis |
| title_full |
Infliximab in ulcerative colitis |
| title_fullStr |
Infliximab in ulcerative colitis |
| title_full_unstemmed |
Infliximab in ulcerative colitis |
| title_sort |
infliximab in ulcerative colitis |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/d7d25d975b084e1b95110d58fe7dcd89 |
| work_keys_str_mv |
AT avilevin infliximabinulcerativecolitis AT orenshibolet infliximabinulcerativecolitis |
| _version_ |
1718403409334239232 |